PTC CLINIC
Informace pro odborníky

Reference

1. www.svod.cz

2. Meredith K.L., Weber J.M., Turaga K.K., Siegel E.M. et al.
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer
Ann. Surg. Oncol. 2010; 4: 1159-67

3. Chirieac L.R., Swisher S.G., Ajani J.A., Komaki R.R. et al.
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
Cancer 2005; 103:1347-55

4. Ono T., Wada H., Ishikawa H., Tamamura H. et al.
Clinical results of proton beam therapy for esophageal cancer: Multicenter retrspective study in Japan
Cancers 2019; 11:993

5. Zhang W., Luo Y., Wang X., Han G. et al.
Dose-escalated radiotherapy improved survival for esopahgeal cancer aptients with a clinical complete response after stadnard-dose radiotherapy with concurrent chemotherapy
Cancer Management and Research 2018; 10:2675-2682

6. Akiyama H. et al.
Principles of surgical treatment for carcinoma of the esopahagus: Analysis of lymphnode involvement.
Ann. Surg. 1981; 194:438

7. Chen J., Suoyan L., Pan J., Zheng X. et al.
The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma.
European Journal of Cardio-thracic Surgery 2009; 36: 480-486

8. Sharma S. et al.
Patterns of lymph-node metastasis in 3-field dissection for carcinoma in the thoracic oesopahgus
Surg. Today 1994; 24:410

9. Wang J., Wei C., Tucker S.L., Myles B. et al.
Predictors of postoperative complications after trimodality therapy for esophageal cancer
Int J Radiat Oncol Biol Phys. 2013;86:885-91

10. Casson A.G. et al.
Lymphnode mapping of esophageal cancer
Ann. Thorac. Surg. 1994; 58:1569

11. www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

12. Lordick F., Mariette C. Haustermans K., Obermannova R. et al.
Oesopahgeal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann. Oncol. 2016; 27 (Suppl. 5): v60-v67

13. Minsky B., Pajak T.F., Ginsberg R., Pisansky T.M. et al.
INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy
J. Clin. Oncol. 2002; 20:1167-74

14. Yamashita H., Okuma K., Wakui R., Kobayashi-Shibata S. et al.
Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracici esophageal squamaous cell carcinoma – a retrspective analysis
Radiother. Oncol. 2011; 98:255-260

15. Onozawa M., Nihei K., Ishikura S. et al.
Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus
Radiother. Oncol. 2009; 92: 266-269

16. Di Fiore F., Lecleire S., Rigal O. et al.
Predictive factors of survival in patients treated with definitive chemoradiotehrapy for squamous cell esophageal carcinoma
World J. Gastroenterol. 2006; 12:4185-4190

17. Suh Y.G., Lee I.J., Koom W.S. et al.
High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer
Jpn. J. Clin. Oncol. 2014; 44:534-540

18. He L., Allen P.K., Potter A. et al.
Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esopahgeal squamous cell carcinoma
J. Thorac. Oncol. 2014; 9:1398-1405

19. Zhang W., Luo Y., Wang X., Han G. et al.
Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard dose radiotherapy with concurrent chemotherapy
Cancer management and Research 2018; 10:2675-2682

20. Fan C-Y., Su Y-F. Huang W-Y, Chao H-L et al.
Definitive radiotherapy dose escalaltion with chemotherapy for treating non-metastatci oesophageal cancer
Scientific reports 2018; 8:12877

21. Viklund P., Lindblad M., Lu M., Ye W., Johansson J.
Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden
Ann Surg. 2006 ;243:204-11

22. Bosch D.J., Muijs C.T., Mul V.E., Beukema J.C.
Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
Ann Surg Oncol. 2014; 21:605-11

23. Shiraishi Y., Fang P., Xu C., Song J. et al.
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018; 128:154-160

24. Wang J., Wei C., Tucker S.L., et al.
Predictors of postoperative complications after trimodality therapy for esophageal cancer.
Int J Radiat Oncol Biol Phys. 2013; 86:885-91

25. Van der Werf L., Busweiler L.A.D., van Sandick J.W. et al.
Reporting National Outcomes After Esophagectomy and Gastrectomy According to the Esophageal Complications Consensus Group (ECCG)
Annals of Surgery 2019 Jan 19. doi: 10.1097/SLA.0000000000003210. [Epub ahead of print]

26. Lee H.K. Vaporciyan A.A., Cox J.D. et al.
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters.
Int J Radiat Oncol Biol Phys. 2003; 57:1317-22

27. Lin S.H., Merrell K.W., Bhooshan N., Correa A.M.
Radiation modality use and the icidence of pstoperative complications and legth of hospitalization after trimodality therapy for esophageal cancer: A multiinstitutional analysis.
Int. J. Radiat. Oncol. Biol. Phys. 2019; 105; Suppl. 1, Abst. 27, S12

28. Lin S.H., Hobbs B.,Thall P.,Tidwell R.S. et al.
Results of a Phase II Randomized Trial of Proton Beam Therapy vs Intensity Modulated Radiation Therapy in Esophageal Cancer
Int. J. Radiat. Oncol. Biol. Phys. 2019; 105: 680–681
29. Thomas M., Defraene G., Lambrecht M., Deng W. et al.
NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer.
Radiother Oncol. 2019;141:33-40

30. Haj M. N., De Rooij S., Hulshof M. et al.
Activities of daily living and quality of life during treatment with neoadjuvant chemoradiotherapy and after surgery in patients with esophageal cancer
J Surg Oncol. 2016;114:684-690

31. Wang J., Wei C., Myles B., Cox J.D. et al..
Radiation Modality is a Strong Predictor for Postoperative
Pulmonary and GI Complications After Trimodality Therapy for
Esophageal Cancer
Int. J. Radiat. Oncol. Biol. Phys. 2019; 105; Suppl. 1, Abst. 100, S40

32. Lin J.B. , Hung L-C. , Cheng C-Y., Chien Y-A et al.
Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy
Radiat. Oncol. 2019; 14:85

33. Kato K., Muro K., Minashi K., Ohtsu A. et al.
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 684–690

34. Nishimura Y.,Mitsumori M., Hiraoka M., Koike, R. et al.
A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for
esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).
Radiother. Oncol. 2009, 92, 260–265

35. Makishima H., Ishikawa H., Terunuma T., Hashimoto, T. et al.
Comparison of adverse e_ects of proton and X-ray chemoradiotherapy
for esophageal cancer using an adaptive dose-volume histogram analysis
J. Radiat. Res. 2015, 56, 568–576.

36. Hirano Y., Onozawa M, Hojo H. Motegi A. et al.
Dosimetric comparison between proton beam therapy and photon radiation therapy for
locally advanced esophageal squamous cell carcinoma
Radiat. Oncol. 2018, 13: 23

37. Hayashi K., Fujiwara Y., Nomura M., Kamata M. et al.
Predictive factors for pericardial e_usion identified by heart dose-volume histogram analysis in oesophageal
cancer patients treated with chemoradiotherapy
Br. J. Radiol. 2015, 88: 20140168.

38. Frandsen J., Boothe D., Gffney D.K.,Wilson B.D. et al.
Increased risk of death due to heart disease after radiotherapy for esophageal cancer.
J. Gastrointest. Oncol. 2015; 6:516–523.

39. Welsh J., Gomez D., Palmer M.B., Riley B.A. et al.
Intensity-modultaed proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study
Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 1336 – 1342

40. Zhang X., Zhao K., Guerrero T.M., McGuire S.E. et al.
Four-dimensional computera tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esopahgeal cancer
Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 278-287

41. Makishima H., Ishikawa H., Terunuma T., Hashimoto T. et al.
Comparison of adverse effects on proton and X-ray chemoradiotehrapy for esophageal cancer using and adaptive dose-volume histogram analysis
Journal of Radiation Research 2015; 56:568-576

42. Wang J., Wei C., Tucker S.L., Myles B. et al.
Predictors of postoperative complications after trimodality therapy for esophageal cancer
Int. J. Radiat. Oncol. Biol. Phys. 2013; 86:885-891

43. Makishima H., Ishikawa H., Terunuma T., Hashimoto T. et al.
Comparison of adverse effects of proton and X-ray chemoradiotherapy
for esophageal cancer using an adaptive dose-volume histogram analysis
J. Radiat. Res. 2015, 56, 568–576

44. Mizumoto M., Sugahara S., Nakayama H., Hashii H. et al.
Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer
Strahlenther. Onkol. 2010; 186:482-488

45. Sugahara S., Tokuuye K., Okumura T., Nakahara A. et al.
Clinical results of proton beam therapy for cancer of the esophagus
Int. J. Radiat. Oncol. Biol. Phys. 2005; 61:76-84

46. Mizumoto M., Sugahara S., Okumura T., Hashiomoto M. et al.
Hyperfractionated concomitant boost proton beam therapy for esophageal carcinoma
Int. J. Radiat. Oncol. Biol. Phys. 2011; 81:601-606

47. Lin S.H., Komaki R., Liao Z., Wei C. et al.
Proton beam therapy and concurrent chemotherapy for esophageal cancer
Int. J. Radiat. Oncol. Biol. Phys. 2012; 83:345-351

48. Koyama S., Tsujii H.
Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas
Clin. Cancer Res. 2003; 9:3571-7

49. https://clinicaltrials.gov/ct2/show/NCT03801876

50. VÍTEK, Pavel. Neuroendokrinní tumor ilea – diagnóza po dvou letech a léčba převážně chirurgická. Neuroendocrine Tumors News. 2019 4(2), 9-12. ISSN  2533-5227. https://www.worldmednet.cz/neuroendokrinni-tumor-ilea-diagnoza-po-dvou-letech-a-lecba-prevazne-chirurgicka/

51. Vítek Pavel, Jiří Kubeš Co přináší protonová radioterapie nádorů jícnu

52. Pavel Vítek, Jiří Kubeš, Kateřina Jiránková, Vladimír Vondráček. Definitivní protonová chemoradioterapie u nádorů krčního jícnu – předběžná analýza výsledků. Onkologie. 2024:18(1):53-58 | DOI: 10.36290/xon.2024.011